Excellent overview of #sabcs18 by @DrSusanLove , with a call for more metastatic research!
www.drsusanloveresearch.org/blogs/overview-san-anton... via @AddThis
We may be meeting IRL but @IBCResearch @ShehasMBC @coffeemommy are all on tweeting! #bcsm @ #sabcs18
And another selfie with an oncologist/researcher I’m so grateful to be working with-
Dr Yuan Yuan of @cityofhope #sabcs18 #bcsm
How many conferences have @Nikhilwagle and I taken a selfie?? So grateful to be #NotDeadYet and to know this man who is working so, so hard for us. @MBC_Project @count_me_in #sabcs18 #bcsm
Was it a breast cancer conference or prom?? With @jrgralow @lyndaweatherby @TPollastro (and why am I the only one holding a glass / I know the rest of you had one too!) #sabcs18 #bcsm
Love Dr Doug Yee’s analogy: DNA is like beads on a string - the beads are the exsomes that code for the RNA that makes the proteins. Exsomes account for 1% of the whole DNA bead and string. Whole genome sequencing looks at the “string” between the exsomes too.
#SABCS18 #bcsm
Important results from the KATHERINE trial for early stage HER2+ patients that will likely be practice changing: adjuvant TDM-1 instead of trastuzamab #SABCS18 #bcsm
.@Nikhilwagle talking about the @MBC_Project!! Patient driven research for the win! #SABCS18 #bcsm MAJOR #COI (❤️❤️❤️❤️ #MBCProject and the entire team especially @corrie_painter!)
DNA sequencing is NOT the whole story; there are many other factors, including RNA, tumor microenvironment, proteomics, #SABCS18 #bcsm #COI
These differences in genomic landscape between early stage and MBC may have clinical implications, BUT a mutation or pathway may not actually be functional. Can be used to direct research, however. #SABCS18 #bcsm #COI
Summary of how MBC is different than primary (most of the differences were seen in ER+ MBC, and most patients were ER+ #SABCS18 #bcsm #COI
Always thrilled to hear a great friend to the MBC community, @Nikhilwagle #SABCS18 #bcsm #COI (I’m a member of the @count_me_in team and flat-out ❤️Nik!)
And now info on genomic landscape of MBC in France by @FAndreMD: 23 driver mutations identified in early and mets, 9 enriched in MBC overall, 10 in ER+ MBC #SABCS18 #BCSM
Bottom line from IMpassion130: if you’re metastatic TNBC you should be tested for PD-L1 expression on immune cells and if positive, consider atezolizumab + abraxane. #SABCS18 #bcsm
IMPassion 130 showed a 10 month improvement in overall survival in metastatic TNBC patients with PD-1 expression on immune cells . The combo of atezolizumab + abraxane is exciting IN THIS POPULATION OF PATIENTS. #SABCS18 #bcsm
Excited to hear a researcher, for whom I’m advocate, speak at #SABCS18 especially since Dr Bussard works on bone mets. #bcsm
@BCRFcure spent $23.8 million (of $63 million) on metastatic research, Dr Margaret Flowers reports at the @mbcalliance meeting at #sabcs18 #bcsm